| News
Basel’s Lyfegen closes seed financing round
18.04.2019
Lyfegen, an IT company specializing in healthcare from Basel, has raised 750,000 Swiss francs in a seed financing round. The startup has developed a software solution to overcome technical hurdles in value-based healthcare.

The founding team of the Lyfegen HealthTech AG
Value-based healthcare puts the spotlight on the successful treatment of patients. This involves assessing the outcome of treatment as a whole, rather than focusing on the quantity of drugs prescribed or medical appointments. In Lyfevalue, Basel startup Lyfegen has developed a platform that enables life sciences companies, national and private healthcare payers and healthcare providers to execute value-based pricing contracts. Lyfegen has now successfully closed its seed financing round, led by Swiss private investors, raising a total of 750,000 francs, it was reported in a press release.
Founded in October 2018, Lyfegen HealthTech AG will use these funds to further build its platform and conduct new pilot projects with partners in Africa, the EU and the USA. Lyfegen will therefore offer a platform that allows healthcare providers to operationalize value-based healthcare strategies, while fostering accelerated and facilitated access to innovative treatments for patients. “Enabling the shift to sustainable healthcare is a huge challenge, giving us at Lyfegen great purpose,” said Girisha Fernando, Lyfegen’s CEO & Founder.
The founders – Michel Mohler, Nico Mros, Leon Rebolledo and James Gannon, in addition to Girisha Fernando – previously worked at companies including Roche, Novartis and UBS. Subsequently, they created their software solution for Lyfegen to enter a market set to grow to US$390.7 billion by 2024, according to the press release. Lyfegen is accompanied and supported on its way by BaselArea.swiss.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
BeiGene opens European headquarters in Basel
BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...
Read MoreThe 25 Best AI Courses in the Basel Area, Germany and France
Artificial Intelligence (AI) offers numerous possible applications. But how, where and regarding which focal points can you get further training...
Read MoreEngimmune Therapeutics banks 15.5 million Swiss francs
Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies...
Read MoreBionter receives 3 million US dollars in investments
Bionter AG has received 3 million US dollars in a seed funding round. These funds will enable Bionter to bring...
Read MoreResistell seeking to further develop test to combat antibiotic resistance
The startup Resistell has launched a study looking into the applicability of a test against antibiotic resistances that is being...
Read MoreBiotech startup Cimeio receives 46 million Swiss francs for cell therapy
Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is...
Read MoreSuperlab Suisse heading to Basel
Superlab Suisse is bringing its Lab-as-a-Service business concept to Basel. The company will open a new location with lab and...
Read MoreSwiss TPH opens new building on the site of BaseLink
The Swiss Tropical and Public Health Institute has officially opened its multifunctional new building at the Basel Area’s new life...
Read MoreWorld first in the Switzerland Innovation Park Basel Area
Eldico Scientific has opened the world’s first experience center for electron diffractometry in the site Allschwil of the Switzerland Innovation...
Read MoreDayOne healthtech accelerator launches new offering
DayOne shares the launch of DayOne Accelerator 2.0, marking a transition to three verticals that will enable the growth of...
Read More